Volrustomig Clinical Trials

14 actively recruiting trials across 9 locations

Also known as: MEDI5752, Other Name: MEDI5752

Pipeline

Early 1: 2Phase 1: 1Phase 2: 9Phase 3: 2

Top Sponsors

AstraZeneca11
Presage Biosciences2
University of Chicago1

Indications

Cancer14
Lung Cancer4
Gastric Cancer3
Liver Disease2
Biliary Tract Cancer2

Los Angeles, California4 trials

Novel Combinations in Participants With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma

Research Site

Phase 2

Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)

Research Site

Phase 2

Study of Volrustomig as Monotherapy or in Combination With Anti- Cancer Agents in Participants With Advanced/Metastatic Solid Tumors

Research Site

Phase 2

Volrustomig Priming Regimens Exploratory Phase II Platform Study

Research Site

Phase 2

Birmingham, Alabama2 trials

Study of Novel Immunomodulators as Monotherapy and in Combination With Anticancer Agents in Participants With Advanced Hepatobiliary Cancer

Research Site

Phase 2

Study of Volrustomig in Women With High Risk Locally Advanced Cervical Cancer (eVOLVE-Cervical)

Research Site

Phase 3

Sacramento, California2 trials

PBI-MST-01 (NCT04541108) Substudy AZN-05: Intratumoral Microdosing of Rilvegostomig, Volrustomig, Sabestomig, and AZD9592 in HNSCC

UC Davis

Early 1

Phase 0 Master Protocol for CIVO Intratumoral Microdosing of Anti-Cancer Therapies

UC Davis

Early 1

Phoenix, Arizona1 trial

MEDI5752 in Combination With Carboplatin Plus Pemetrexed in Unresectable Pleural Mesothelioma

Research Site

Phase 3

Scottsdale, Arizona1 trial

A Study of Novel Study Interventions and Combinations in Participants With Colorectal Cancer

Research Site

Phase 2

Little Rock, Arkansas1 trial

Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer

Research Site

Phase 2

Duarte, California1 trial

Phase Ib Study of the Safety of T-DXd and Immunotherapy Agents With and Without Chemotherapy in Advanced or Metastatic HER2+, Non-squamous NSCLC

Research Site

Phase 1

Santa Monica, California1 trial

Ph1b/2 Study of the Safety and Efficacy of T-DXd Combinations in Advanced HER2-expressing Gastric Cancer (DESTINY-Gastric03)

Research Site

Phase 2

Chicago, Illinois1 trial

Response-Adaptive Treatment in Untreated Locoregional HPV-Negative Head and Neck Cancer

The University of Chicago

Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.